Katja Madeyski-Bengtson

TL;DR: This study provides the first evidence that a Pnpla3 ASO therapy can improve all features of NAFLD, including liver fibrosis, and suppress the expression of a strong innate genetic risk factor, PnPla3 148M, which may open up a precision medicine approach in NASH.

TL;DR: It is shown that in the intestinal epithelial surface, PGC1α drives mitochondrial biogenesis and respiration in the presence of reduced antioxidant enzyme activities, thus determining the accumulation of reactive oxygen species and fostering the fate of enterocytes toward apoptosis.

TL;DR: A novel computational platform called Rational InDel Meta-Analysis (RIMA) is presented that enables an in-depth comprehensive analysis of Cas9-induced genetic alterations, especially InDels mutations, and can be used to quantitate the contribution of classical microhomology-mediated end joining (c-MMEJ) pathway in the formation of mutations at Cas9 target sites.

TL;DR: A humanized mouse model with liver-specific expression of human PCSK9 and a human-like hypercholesterolemia phenotype is described, and it is demonstrated that this mouse can be used to evaluate antibody and gene editing-based (genome and base editing) therapies to modulate the expression ofhuman PCSK 9 and reduce cholesterol levels.

TL;DR: This study shows that mimicking of genetic susceptibility, expressed as DILI-associated HLA-types in mice, is not sufficient for reproducing the complex pathogenesis leading to D ILI in man.